IMPACTfolio LLC Purchases Shares of 2,904 Edwards Lifesciences Co. (NYSE:EW)

IMPACTfolio LLC acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,904 shares of the medical research company’s stock, valued at approximately $215,000.

Several other large investors also recently made changes to their positions in EW. Purus Wealth Management LLC increased its position in Edwards Lifesciences by 5.2% during the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after buying an additional 160 shares during the last quarter. JFS Wealth Advisors LLC boosted its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the period. Seascape Capital Management increased its holdings in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after acquiring an additional 174 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its stake in Edwards Lifesciences by 1.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after acquiring an additional 184 shares during the period. Finally, Martin Capital Advisors LLP lifted its holdings in Edwards Lifesciences by 0.7% during the 3rd quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock valued at $1,686,000 after purchasing an additional 186 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on EW shares. Citigroup upped their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, Evercore ISI dropped their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Sixteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.40.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,500 shares of company stock worth $2,508,350. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW traded down $1.34 on Thursday, hitting $72.69. 3,399,019 shares of the company’s stock were exchanged, compared to its average volume of 4,694,415. The stock has a 50-day moving average of $70.94 and a 200-day moving average of $72.83. The stock has a market cap of $42.87 billion, a price-to-earnings ratio of 10.49, a P/E/G ratio of 3.63 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the company earned $0.59 EPS. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. Analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.